A recent analysis of last year’s FOURIER trial has found evolocumab, a PCSK9 inhibitor developed to treat hyperlipidemia, can robustly reduce low-density lipoprotein cholesterol (LDL-C) in patients without any major concern for individual-level variability in response.
Using coronary CT angiography to identify which patients with suspected coronary artery disease (…
Questioning older patients about their weight earlier in life could be a low-tech, low-cost way to…
A report issued Dec. 14 by the Campaign for Tobacco-Free Kids, American Heart Association and Truth…
The implantable cardioverter defibrillator (ICD) market is projected to grow to $4.3 billion by…
Women with atherosclerotic cardiovascular disease (ASCVD) were more likely to report worse…
Colorado residents who live in close proximity to oil and natural gas extraction sites might…